These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6840121)

  • 21. Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.
    Packer M; Meller J; Medina N; Yushak M; Gorlin R
    N Engl J Med; 1982 Jan; 306(2):57-62. PubMed ID: 7053487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined prazosin and hydralazine in resistant hypertension.
    Russell GI; Swart S; Bing RF; Thurston H; Swales JD
    Lancet; 1980 Mar; 1(8167):543. PubMed ID: 6102261
    [No Abstract]   [Full Text] [Related]  

  • 23. [Vasodilator agents in chronic heart failure: which is the best option?].
    Corbalán R; Kunstmann S; Jalil J
    Rev Med Chil; 1993 Jan; 121(1):81-8. PubMed ID: 8235172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Afterload reduction in the treatment of cardiac failure.
    Mason DT
    Schweiz Med Wochenschr; 1978 Nov; 108(44):1695-703. PubMed ID: 102028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of vasodilator therapy on mortality in chronic congestive heart failure.
    Cohn JN
    Eur Heart J; 1988 Jan; 9 Suppl A():171-3. PubMed ID: 3044793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vasodilator therapy with prazosin for severe congestive heart failure--hemodynamic effects of oral single administration and chronic use (author's transl)].
    Akamatsu T; Suzuki A; Yamamoto T; Takahashi S; Kimata S; Hirosawa K
    Kokyu To Junkan; 1979 Sep; 27(9):991-7. PubMed ID: 538350
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.
    Chatterjee K; Ports TA; Arnold S; Brundage B; Parmley W
    Br Heart J; 1979 Dec; 42(6):657-63. PubMed ID: 534582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapies in the management of congestive heart failure.
    Atkins FL
    J Kans Med Soc; 1980 Feb; 81(2):83-5, 94. PubMed ID: 7351512
    [No Abstract]   [Full Text] [Related]  

  • 29. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
    Cohn JN; Archibald DG; Francis GS; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Flohr KH
    Circulation; 1987 May; 75(5 Pt 2):IV49-54. PubMed ID: 3552302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hypotensive effect and tolerability of a short course of treatment with prazosin (pratsiol) and hydralazine (apressin) in a cooperative study of new drugs for the prevention of arterial hypertension].
    Kardiologiia; 1985 Jan; 25(1):23-8. PubMed ID: 3981857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Danger of withdrawal of vasodilator therapy in patients with chronic heart-failure.
    Hanley SP; Cowley A; Hampton JR
    Lancet; 1980 Apr; 1(8171):735-6. PubMed ID: 6103157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasodilator therapy for chronic congestive heart failure.
    Abrams J
    JAMA; 1985 Dec; 254(21):3070-4. PubMed ID: 3932697
    [No Abstract]   [Full Text] [Related]  

  • 33. Vasodilators for chronic congestive heart failure.
    Med Lett Drugs Ther; 1988 Jan; 30(758):13-4. PubMed ID: 3277025
    [No Abstract]   [Full Text] [Related]  

  • 34. [The effects of prazosin in patients with chronic refractory heart failure-acute hemodynamic effects of oral prazosin and long-term therapy (author's transl)].
    Honda T; Hiramori K; Haze K; Saito M; Fuseno H; Fukami K; Umemoto M; Tanaka N; Ikeda M
    Kokyu To Junkan; 1981 May; 29(5):527-35. PubMed ID: 7313357
    [No Abstract]   [Full Text] [Related]  

  • 35. Oral vasodilator therapy for chronic heart failure: a plea for caution.
    Packer M; Meller J
    Am J Cardiol; 1978 Oct; 42(4):686-9. PubMed ID: 358821
    [No Abstract]   [Full Text] [Related]  

  • 36. Serial hemodynamic studies during the treatment of congestive heart failure with isolated low-dose oral prazosin therapy.
    Reyns PR; Romney D; Desser KB; Benchimol A
    Angiology; 1979 Dec; 30(12):850-5. PubMed ID: 533015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of peripheral vasodilators with different mechanisms of action in treating heart failure patients].
    Novikov SV; Mareev VIu; Elizarova NA; Naumov VG; Sazonova LN
    Ter Arkh; 1987; 59(9):126-30. PubMed ID: 3424177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of vasodilator treatment of chronic circulatory insufficiency on various polycardiographic parameters].
    Guzińska B; Nartowicz E
    Kardiol Pol; 1983; 26(7):565-70. PubMed ID: 6645153
    [No Abstract]   [Full Text] [Related]  

  • 39. Prazosin in chronic congestive heart failure due to ischemic heart disease.
    Antani JA; Antani NJ; Nanivadekar AS
    Clin Cardiol; 1991 Jun; 14(6):495-500. PubMed ID: 1810687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.